Adams Respiratory Therapeutics initiated with "buy" - update

08/30/05 - Deutsche Securities

NEW YORK, August 30 (newratings.com) - Analyst David Steinberg of Deutsche Bank Securities initiates coverage of Adams Respiratory Therapeutics (ARXT) with a "buy" rating. The target price is set to $40.

In a research note published this morning, the analyst mentions that the company possesses the attractive features of both the OTC and the branded pharmaceutical business models. Deutsche Bank Securities expects Adams Respiratory Therapeutics to witness robust earnings and revenue growth during the forthcoming three years.